Isoform-Selective PI3K Modulators for Hematologic Malignancies

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a significant need for improved therapy for cancers, particularly hematologic malignancies, which have a high expression level of PI3K isoforms such as PI3K-δ and/or PI3K-γ, as current treatments are not selective enough to target these specific isoforms effectively.

Innovation Solution

The development of isoform-selective PI3K modulators that selectively inhibit the activity of PI3K-δ and/or PI3K-γ, either alone or in combination with other agents, to treat or prevent hematologic malignancies with high expression levels of these isoforms, using biomarkers to identify suitable patients and personalized treatment strategies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-selective PI3K inhibitors are used to treat cancers with high PI3K expression, then broad PI3K pathway inhibition is achieved, but adverse effects increase due to lack of isoform specificity

Engineering Contradiction:

Improvetreatment efficacyVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the PI3K inhibitor class into isoform-specific compounds that selectively inhibit individual PI3K isoforms (α, β, γ, or δ) rather than all isoforms. This segmentation allows targeted inhibition of the specific isoform driving cancer growth while preserving other isoforms that perform normal physiological functions, thereby reducing adverse effects while maintaining treatment efficacy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by designing inhibitors with selective binding properties for specific PI3K isoforms based on their unique structural features. Each isoform-specific inhibitor is tailored to recognize and bind to the distinct catalytic domain characteristics of its target isoform, enabling localized inhibition of only the pathological isoform while leaving other isoforms unaffected.

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If isoform-selective PI3K modulators are developed to target specific PI3K-δ and/or PI3K-γ, then adverse effects are reduced, but device complexity and development difficulty increase

Engineering Contradiction:

Improveadverse effectsVSAvoiddrug development complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent employs parameter changes by modifying the chemical structure of PI3K inhibitors to alter their binding specificity. By changing structural parameters such as substituent groups, molecular geometry, and binding affinity characteristics, the patent develops compounds that selectively target specific PI3K isoforms. This systematic variation of molecular parameters enables isoform selectivity while providing a framework for rational drug design that manages development complexity.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250319091A1Treatment of cancers using PI3 kinase isoform modulators

Publication Date: 2025.10.16 INFINITY PHARMACEUTICALS INC

AI summary

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.